Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis

Trial Profile

Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2016

At a glance

  • Drugs Immunoglobulin G (Primary) ; Glatiramer acetate; Interferon beta-1a; Interferon beta-1b
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms PREDICT
  • Sponsors Octapharma
  • Most Recent Events

    • 01 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 18 Dec 2013 Trial design has been presented at the European Charcot Foundation annual meeting, according to an Octapharma media release.
    • 18 Dec 2013 The first 2 patients have been enrolled in Bulgaria, according to an Octapharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top